Demographic characteristics of the patients at baseline
| Characteristics | PNPLA3 CC (n=21) | PNPLA3 CG/GG (n=24) |
| Mean age in years (range) | 59.3 (48–83) | 56.4 (41–67) |
| Number of males | 12 (57%) | 15 (63%) |
| Mean BMI (range) | 32.8 (19–47) | 29.6 (18–37) |
| Number of patients by race | ||
| White | 19 (96%) | 23 (98%) |
| Black | 1 (2%) | 0 (0%) |
| Hispanic | 1 (2%) | 1 2%) |
| Number of patients with diabetes | 3 (33%) | 9 (38%) |
| Mean CT scan liver minus spleen attenuation (range, n) | 9.8 (5–16, n=8) | 11.9 (6–26, n=14) |
| Number of patients reporting previous heavy alcohol use | 9 (43%) | 14 (58%) |
| Number of patients by HCV genotype | ||
| 1 | 13 (62%) | 19 (79%) |
| 2 | 4 (19%) | 3 (13%) |
| 3 | 4 (19%) | 2 (8%) |
| HCV RNA | ||
| Mean log10 IU/mL (range) | 5.9 (4.0–6.9) | 5.6 (3.6–6.4) |
| Number of patients with ≥800 000 IU/mL | 7 (47%) | 4 (33%) |
| Number of patients with decompensated cirrhosis | ||
| Child-Pugh class B | 14 (67%) | 19 (79%) |
| Child-Pugh class C | 7 (33%) | 5 (21%) |
| BE3A score14 | ||
| 0 | 8 (38%) | 8 (33%) |
| 1 | 7 (33%) | 8 (33%) |
| 2 | 6 (29%) | 5 (21%) |
| 3 | 0 (0%) | 3 (13%) |
| Mean Child-Pugh score | 8.8 (1.6) | 8.4 (1.6) |
| Mean MELD score | 13.4 (4.2) | 12.2 (2.4) |
| Number of patients with previous HCV treatment | 6 (38%) | 4 (29%) |
| Number of patients by protease inhibitor-containing direct antiviral regimen | 5 (23.8%) | 5 (20.8%) |
| Ribavirin-containing regimen | 11 (52.4%) | 12 (50.0%) |
| Number of patients by treatment duration | ||
| 12 weeks | 14 (66.7%) | 14 (58.3%) |
| 16 weeks | 0 (0%) | 1 (4.2%) |
| 24 weeks | 7 (33%) | 9 (37.5%) |
No baseline differences were statistically significant.
BMI, body mass index ; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease.